$BFNH
BIOFORCE NANOSCIENCES HOLDINGS, INC.

2022 Q4 Form 10-Q Financial Statement

#000109181822000145 Filed on November 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $114.7K $122.6K $113.9K
YoY Change -4.94% 7.67% -3.44%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $114.7K $122.6K $113.9K
YoY Change -4.94% 7.66% -3.44%
Operating Profit -$114.7K -$122.6K -$113.9K
YoY Change -4.94% 7.66% -3.44%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$114.7K -$122.6K -$113.9K
YoY Change -4.94% 7.67% -3.44%
Income Tax
% Of Pretax Income
Net Earnings -$114.7K -$122.6K -$113.9K
YoY Change -4.94% 7.66% -3.44%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 -$3.890K
COMMON SHARES
Basic Shares Outstanding 29.27M shares 29.27M shares 29.27M shares
Diluted Shares Outstanding 29.27M shares 29.27M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $730.00 $750.00 $27.31K
YoY Change -93.43% -97.25% -31.5%
Cash & Equivalents $734.00 $750.00 $27.31K
Short-Term Investments
Other Short-Term Assets $0.00 $0.00 $70.00
YoY Change -100.0% -100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $734.00 $750.00 $27.38K
YoY Change -93.41% -97.26% -31.33%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $734.00 $750.00 $27.38K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $734.00 $750.00 $27.38K
YoY Change -93.41% -97.26% -31.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $400.00 $840.00 $440.00
YoY Change -93.66% 90.91%
Accrued Expenses $1.174M $1.068M $644.8K
YoY Change 56.36% 65.6% 191.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.348M $1.233M $768.5K
YoY Change 54.41% 60.47% 177.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.348M $1.233M $768.5K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.348M $1.233M $768.5K
YoY Change 54.41% 60.47% 177.24%
SHAREHOLDERS EQUITY
Retained Earnings -$160.2M -$160.0M
YoY Change 0.3%
Common Stock $158.8M $158.8M
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.347M -$1.233M -$741.2K
YoY Change
Total Liabilities & Shareholders Equity $734.00 $750.00 $27.38K
YoY Change -93.41% -97.26% -31.33%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$114.7K -$122.6K -$113.9K
YoY Change -4.94% 7.66% -3.44%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$9.430K -$16.39K -$8.680K
YoY Change 4.31% 88.82% 0.46%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.420K 7.910K 8.680K
YoY Change -231.56% -8.87% 0.46%
NET CHANGE
Cash From Operating Activities -9.430K -16.39K -8.680K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 9.420K 7.910K 8.680K
Net Change In Cash -10.00 -8.480K 0.000
YoY Change -99.94%
FREE CASH FLOW
Cash From Operating Activities -$9.430K -$16.39K -$8.680K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
164681 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
116178 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1233292 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
873008 usd
us-gaap Net Income Loss
NetIncomeLoss
-370779 usd
CY2022Q3 us-gaap Liabilities
Liabilities
1233292 usd
CY2021Q4 us-gaap Liabilities
Liabilities
873008 usd
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
29272 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
29272 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158781227 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158781127 usd
CY2022Q3 us-gaap Revenues
Revenues
usd
CY2021Q3 us-gaap Revenues
Revenues
usd
us-gaap Net Income Loss
NetIncomeLoss
-381254 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-40 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160043041 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159672262 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1232542 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-861863 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
750 usd
us-gaap Revenues
Revenues
usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11145 usd
us-gaap Revenues
Revenues
usd
CY2022Q3 us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
105750 usd
CY2021Q3 us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
105750 usd
us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
317250 usd
us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
317250 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16837 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
70 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8110 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5469 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
53529 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
64004 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4655 usd
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
317250 usd
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
317250 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
122587 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
113860 usd
us-gaap Operating Expenses
OperatingExpenses
370779 usd
us-gaap Operating Expenses
OperatingExpenses
381254 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-122587 usd
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
NONE
dei Trading Symbol
TradingSymbol
NONE
dei Security Exchange Name
SecurityExchangeName
NONE
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29271755 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
750 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11105 usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58958 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
40 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
750 usd
us-gaap Interest Paid Net
InterestPaidNet
usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
11145 usd
CY2022Q3 us-gaap Assets
Assets
750 usd
CY2021Q4 us-gaap Assets
Assets
11145 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
844 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6313 usd
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2022Q3 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
1067767 usd
CY2021Q4 us-gaap Accrued Salaries Current And Noncurrent
AccruedSalariesCurrentAndNoncurrent
750517 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
BIOFORCE NANOSCIENCES HOLDINGS, INC.
dei Entity File Number
EntityFileNumber
000-53505
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
74-3078125
dei Entity Address Address Line1
EntityAddressAddressLine1
2020 General Booth Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Unit 230
dei Entity Address City Or Town
EntityAddressCityOrTown
Virginia Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
23454
dei City Area Code
CityAreaCode
(757)
dei Local Phone Number
LocalPhoneNumber
306-6090
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-113860 usd
us-gaap Net Income Loss
NetIncomeLoss
-370779 usd
us-gaap Net Income Loss
NetIncomeLoss
-381254 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29271755 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29271755 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29271755 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29271755 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68729 usd
us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
100 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
48503 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
56169 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48603 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56169 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-10355 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-12560 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11105 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39865 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
750 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27305 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-627302 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-113860 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-741162 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1110055 usd
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
100 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-122587 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1232542 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-359908 usd
us-gaap Net Income Loss
NetIncomeLoss
-381254 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-741162 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-861863 usd
us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
100 usd
us-gaap Net Income Loss
NetIncomeLoss
-370779 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1232542 usd
CY2020Q2 bfnh Business Acquisition Equity Interests Purchased Number Of Shares
BusinessAcquisitionEquityInterestsPurchasedNumberOfShares
100000 shares
CY2020Q2 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Use Of Estimates
UseOfEstimates
<p style="line-height:11pt; margin:0pt; padding-left:49.5pt; text-indent:-49.5pt; text-align: justify;"><b>Use of Estimates</b></p><p style="line-height:11pt; margin:0pt; padding-left:49.5pt; text-indent:-49.5pt; text-align: justify;"> </p><p style="margin:0pt; text-align: justify;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.</p><p style="margin:0pt; text-align: justify;"> </p>
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
usd
us-gaap Cost Of Revenue
CostOfRevenue
usd
us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
usd
CY2021Q3 us-gaap Gross Profit
GrossProfit
usd
us-gaap Gross Profit
GrossProfit
usd
us-gaap Gross Profit
GrossProfit
usd
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29271755 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29271755 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29271755 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29271755 shares
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
dei Entity Central Index Key
EntityCentralIndexKey
0001310488

Files In Submission

Name View Source Status
0001091818-22-000145-index-headers.html Edgar Link pending
0001091818-22-000145-index.html Edgar Link pending
0001091818-22-000145.txt Edgar Link pending
0001091818-22-000145-xbrl.zip Edgar Link pending
bfnh-20220930.htm Edgar Link pending
bfnh-20220930.xsd Edgar Link pending
bfnhlogo2019001.jpg Edgar Link pending
ex311.htm Edgar Link pending
ex312.htm Edgar Link pending
ex321.htm Edgar Link pending
ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bfnh-20220930_cal.xml Edgar Link unprocessable
bfnh-20220930_lab.xml Edgar Link unprocessable
bfnh-20220930_pre.xml Edgar Link unprocessable
bfnh-20220930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bfnh-20220930_htm.xml Edgar Link completed